Amarin (NASDAQ:AMRN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Amarin (NASDAQ:AMRN) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02, Yahoo Finance reports. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. The company had revenue of $56.52 million during the quarter, compared to the consensus estimate of $51.34 million. During the same quarter in the prior year, the firm earned ($0.04) EPS.

Amarin Stock Up 9.4 %

Shares of AMRN traded up $0.08 during mid-day trading on Thursday, hitting $0.92. 1,479,096 shares of the company’s stock were exchanged, compared to its average volume of 1,940,914. The stock has a market cap of $377.00 million, a price-to-earnings ratio of -6.39 and a beta of 1.95. The firm has a fifty day moving average of $0.95 and a two-hundred day moving average of $0.94. Amarin has a twelve month low of $0.65 and a twelve month high of $1.49.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Amarin has an average rating of “Hold” and a consensus target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.